Dianthus Therapeutics director awarded 6,090 options

Dianthus Therapeutics director Sujay Kango received a grant of stock options covering 6,090 shares of common stock.

Rhea-AI Filing Summary

Dianthus Therapeutics director Sujay Kango received a grant of stock options covering 6,090 shares of common stock. The options have an exercise price of $89.63 per share and expire on May 21, 2036. Following this award, Kango holds 6,090 derivative securities in the form of these options.

According to the vesting terms, all 6,090 underlying shares will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders, provided Kango continues to serve the company through that vesting date.

Insider Trade Summary

Grant/Award: 6,090 shares

Grant/Award 1 txn

Insider KANGO SUJAY

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	6,090	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 6,090 contracts (Direct)

Footnotes (1)

1. F1. The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date.

Key Figures

Option grant size: 6,090 options Exercise price: $89.63 per share Underlying shares: 6,090 shares +2 more

5 metrics

Option grant size 6,090 options Stock Option (Right to Buy) granted to director Sujay Kango

Exercise price $89.63 per share Conversion or exercise price of granted stock options

Underlying shares 6,090 shares Common stock underlying the new option award

Expiration date May 21, 2036 Option term end date for the 6,090-share grant

Post-grant derivative holdings 6,090 options Total derivative securities held following this transaction

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, vesting, Annual Meeting of Stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

vesting financial

"shares of common stock underlying this stock option award will vest in full"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Annual Meeting of Stockholders financial

"earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Sujay Kango acquire in this Dianthus Therapeutics (DNTH) Form 4 filing?

Sujay Kango received a grant of stock options for 6,090 shares of Dianthus Therapeutics common stock. These options are a form of equity compensation and give him the right to buy shares at a fixed exercise price if vesting conditions are met.

What is the exercise price of Sujay Kango’s new Dianthus Therapeutics options?

The granted options have an exercise price of $89.63 per share. This means Kango can buy Dianthus Therapeutics common stock at $89.63 for each of the 6,090 underlying shares once the options vest and before they expire on May 21, 2036.

When do Sujay Kango’s Dianthus Therapeutics stock options vest?

All 6,090 underlying shares vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders. Vesting is conditional on Kango’s continued service to Dianthus Therapeutics through the applicable vesting date.

When do Sujay Kango’s newly granted Dianthus Therapeutics options expire?

The stock options granted to Sujay Kango expire on May 21, 2036. After that expiration date, any unexercised portion of the 6,090-share option grant can no longer be used to purchase Dianthus Therapeutics common stock at the specified exercise price.

How many derivative securities does Sujay Kango hold after this Dianthus Therapeutics grant?

Following this grant, Sujay Kango holds 6,090 derivative securities in the form of stock options. Each option corresponds to one share of Dianthus Therapeutics common stock, giving him future purchase rights at the fixed exercise price if the options are exercised.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/22/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KANGO SUJAY

(Last) (First) (Middle)

C/O DIANTHUS THERAPEUTICS, INC.

7 TIMES SQUARE, 43RD FLOOR

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dianthus Therapeutics, Inc. /DE/ [ DNTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$89.63	05/21/2026		A		6,090		(1)	05/21/2036	Common Stock	6,090	$0	6,090	D

Explanation of Responses:

1. The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date.

	/s/ Adam Veness, as attorney-in-fact for Sujay Kango	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)